Muscle Relaxant Drugs Market Anticipated To Reach USD 5.28 Billion By 2030Posted by Neha Bora on August 17th, 2023 San Francisco, 17 Aug 2023: The Report Muscle Relaxant Drugs Market Size, Share & Trends Analysis Report By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030 The global muscle relaxant drugs market size is expected to reach USD 5.28 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.38% from 2023 to 2030. The market is witnessing an increase in the use of relaxant drugs to treat muscle spasticity or spasms. This can be attributed to the growing geriatric population with musculoskeletal disorders, the rising number of surgical procedures, the sedentary lifestyle leading to back pain, work-related musculoskeletal disorders, and other factors leading to increased demand for such agents. For instance, according to an Elsevier article, a December 2021 research found that 64.0% of healthcare workers had a work-related musculoskeletal disease, with lower back pain being the most frequent complaint. Thus, the rising prevalence of such conditions offers a lucrative growth opportunity in the muscle relaxant drugs market. The space has a presence of a diverse group of medications in the management of the condition. These include three FDA-approved drugs, baclofen, tizanidine, and dantrolene to treat spasticity, and six FDA-approved drugs, carisoprodol, metaxalone, methocarbamol, chlorzoxazone, orphenadrine, and cyclobenzaprine indicated to treat muscular spasms. Botulinum toxin is another approved drug for spasticity but is used only for certain cases. Key market players are developing novel therapies and launching new products and generics in the market. For instance, in July 2021, Hikma Pharmaceuticals Plc. announced the launch of 20mg/ml Succinylcholine Chloride Injection indicated for skeletal muscle relaxation associated with surgery or mechanical ventilation in the U.S.; such neuromuscular blocking agents (example: succinylcholine, doxacurium, Cisatracurium, and rocuronium) are important during surgeries. In January 2022, Amneal Pharmaceuticals announced the acquisition of Saol's Baclofen franchise to augment the company's product portfolio with the segment's Lioresal, Lyvispah, and clinical products. However, side effects associated with muscle relaxants might hamper the market's growth. For instance, in 2021, Sandoz recalled 13 lots of oral orphenadrine citrate 100 mg extended-release tablets. A nitrosamine above standard limits was identified in the lots during the testing, which can lead to cancer. Access Research Report of Muscle Relaxant Drugs Market @ https://www.grandviewresearch.com/industry-analysis/muscle-relaxant-drugs-market-report Muscle Relaxant Drugs Market Report Highlights
Muscle Relaxant Drugs Market Report Scope
List of Key Players of Muscle Relaxant Drugs Market
Access Press Release of Muscle Relaxant Drugs Market @ https://www.grandviewresearch.com/press-release/global-muscle-relaxant-drugs-market Like it? Share it!More by this author |